CURRENT
ISSUE
1636

Atogepant (Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (“gepant”), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine.1 Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).

MIGRAINE PREVENTION — Patients with migraine headaches that are frequent, severe, or refractory to acute treatment should...  Continue reading

More from Issue 1636
Previous Issue: 1635      October 18, 2021
Coming Soon
Antiviral Drugs for Influenza for 2021-2022
Drugs for Rheumatoid Arthritis
Ruxolitinib (Opzelura) for Atopic Dermatitis
Clascoterone 1% Cream (Winlevi) for Acne
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release
ADVANCE
RELEASE

Merck and Ridgeback Biotherapeutics have announced that they will submit an application to the FDA for Emergency Use Authorization (EUA) for their investigational oral antiviral drug molnupiravir for treatment of COVID-19.1 If the EUA is granted, molnupiravir would be the first oral antiviral drug to be authorized in the US for treatment of COVID-19. The ... Continue reading

 Tweets